IBRANCE, generically known as palbociclib, is a targeted therapy medication used in the treatment of certain types of breast cancer. Specifically, it is designed for postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. IBRANCE functions as a cyclin-dependent kinase (CDK) inhibitor, primarily inhibiting CDK4 and CDK6. These kinases are proteins that regulate cell division. By inhibiting these proteins, IBRANCE effectively slows down the growth of cancer cells. It is often used in combination with hormone therapy, enhancing the effectiveness of treatment by targeting the cancer cells in multiple ways. As with any medication, it comes with potential side effects, and its use is carefully considered by healthcare professionals based on the individual patient's health status and the specifics of their cancer diagnosis.
When using IBRANCE, it's crucial to adhere to your doctor's instructions and thoroughly read the label that accompanies the medication. This ensures you understand the correct dosage and any potential interactions with other medicines you might be taking. Always inform your doctor about all other medications you are on to avoid adverse reactions. Common side effects of IBRANCE include fatigue, nausea, hair thinning or loss, and an increased risk of infections due to lowered white blood cell counts. Rare but serious side effects can also occur, such as severe lung problems. Given the possibility of experiencing fatigue or weakness, caution is advised when driving or operating heavy machinery until you know how IBRANCE affects you. Monitoring your health and reporting any unusual symptoms to your doctor promptly is essential for managing side effects and ensuring the effectiveness of the treatment.